Cuatrecasas‘s life sciences and healthcare practice regularly assists research institutes and biotech, medical device and cosmetic companies with contentious and non-contentious corporate, competition and regulatory mandates. Elena Cuatrecasas heads up the department and specialises in financing and M&A transactions in the pharma, biotech, healthcare and TMT sectors. Also noted are Jorge Robles, who handles regulatory, contentious and public law matters in the space; and Ariadna Casanueva, who has focused her practice on healthcare compliance and M&A transactions. Gemma Colomer joined from Fieldfisher as counsel in March 2026.
Legal 500 Editorial commentary
Key clients
- Esteve Pharmaceuticals
- Sanofi Ventures
- Merck
- Deepull Diagnostics, Kurma Life Sciences, Asabys Partners
- Platinum Equity
- Faes Farma
- Angelini
- Wellma
- Werfen Group
- Oncomatryx
- Huawei
- Isdin
Work highlights
Advised Sanofi Ventures and EQT on the Series B equity round of SpliceBio, S.L. (€119m).
Advised Werfen on the establishment of a joint venture with SEEGENE in Europe to channel the current distribution of SEEGENE products in Iberia and establish a strategic hub for the development, manufacturing and global distribution of new diagnostic products addressing infectious diseases.
Advising Deepull and its partners on the closing of a Series C financing round (€50m).
Lawyers
Leading associates
Leading associates with regular involvement in their team's key work, and recognition from peers or clients as being ones to watch.
Practice head
Elena Cuatrecasas
Other key lawyers
Jorge Robles; Ariadna Casanueva; Gemma Colomer